VVM
TPST icon

Versant Venture Management’s Tempest Therapeutics TPST Stock Holding History

Versant Venture Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$442K Hold
269,772
– – 0.31% 8
2025
Q4 		$774K Hold
269,772
– – 0.51% 7
2025
Q3 		$2.77M Hold
269,772
– – 1.31% 8
2025
Q2 		$1.83M Sell
269,772
-1
-0% -$7 2.23% 7
2025
Q1 		$2.59M Hold
269,773
– – 4.3% 6
2024
Q4 		$2.93M Buy
+269,773
New +$3.48M 3.37% 6

Other funds holding TPST

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Versant Venture Management's TPST Position: Q1 2026 in Review

Versant Venture Management held its Tempest Therapeutics (TPST) position steady in Q1 2026 at 269,772 shares worth $442K. The position accounts for 0.31% of the portfolio, ranked #8.

Versant Venture Management first reported a position in TPST in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.93M in Q4 2024. 22 funds tracked by Wall St. Rank hold TPST as of Q1 2026.

  • Versant Venture Management held 269,772 shares of Tempest Therapeutics worth $442K as of Q1 2026.
  • Versant Venture Management left its Tempest Therapeutics share count unchanged in Q1 2026.
  • Tempest Therapeutics made up 0.31% of Versant Venture Management's portfolio in Q1 2026, its #8 holding.
  • Versant Venture Management first reported a position in Tempest Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Versant Venture Management's Tempest Therapeutics position peaked at $2.93M in Q4 2024.
  • 22 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2026.

Based on Versant Venture Management's 13F filing for Q1 2026, filed 5 May 2026.